RecruitingNCT05327699
Ketamine or placebo and decision-making in depression
About this title
Read the official source — NCT05327699Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- AtlantaSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 8, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 140
- Sponsor
- Emory University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05327699
- Official title
Show the full official title
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Atlanta
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Emory University, a university.
Does this study involve medication?
Yes. The study involves medication, including ketamine.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
